DK2445926T3 - Biologisk fremstillede cykliske affinitetstags - Google Patents
Biologisk fremstillede cykliske affinitetstags Download PDFInfo
- Publication number
- DK2445926T3 DK2445926T3 DK10728424.2T DK10728424T DK2445926T3 DK 2445926 T3 DK2445926 T3 DK 2445926T3 DK 10728424 T DK10728424 T DK 10728424T DK 2445926 T3 DK2445926 T3 DK 2445926T3
- Authority
- DK
- Denmark
- Prior art keywords
- pro
- gin
- lys
- cys
- tag
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
1. Enzymatisk fremgangsmåde til tilvejebringelse af et proteinholdigt stof omfattende et polypeptid af interesse og en cyklisk affinitetstag, omfattende trinene: a) tilvejebringelse af mindst et proteinholdigt forløberstof, hvilken forløber omfatter proteinet af interesse og mindst et motiv med den generelle formel X1-Tag-X2, hvori X1 og X2 repræsenterer aminosyrer, hvis sidekæder kan forbindes med et lantibiotisk enzym, som kan danne en thioetherbro mellem rester X1 og X2, hvori X1 er valgt fra gruppen bestående af Dhb, Dha, Thr og Ser, og hvori X2 er Cys eller Lys; eller hvori X1 er Cys eller Lys, og X2 er valgt fra gruppen bestående af Dhb, Dha, Thr og Ser; Tag er en aminosyresekvens, der tjener som affinitetstag, når den cykliseres, hvilken affinitetstag tillader indfangning af det prote-inholdige stof til en specifik bindingspartner af taggen; og hvori motivet N-terminalt kommer efter en lantibiotisk ledersekvens; b) bringe forløberen i kontakt med lantibiotisk enzym LanM, cyklase LanC i tilfælde af en kombination af en dehydrorest og et cystein, eller en kombination af en lantibiotisk dehydrase LanB og cyklase LanC i tilfælde af, at X1 eller X2 er Thr eller Ser, hvilket tillader dannelse af en thioetherbro mellem X1 og X2, så der derved indføres en intramolekylær ringstruktur omfattende Tag-sekvensen; og c) isolering af det resulterende cykliserede proteinholdige stof; forudsat, at fremgangsmåden ikke indebærer en fremgangsmåde til behandling af det menneskelige eller dyriske legeme eller en diagnostisk fremgangsmåde praktiseret på det menneskelige eller dyriske legeme.
2. Fremgangsmåde ifølge krav 1, hvori polypeptidet af interesse er fusioneret N-eller C-terminalt til det mindst ene motiv med den generelle formel X1-Tag-X2.
3. Fremgangsmåde ifølge krav 2, hvori det proteinholdige stof omfatter et spaltningssted mellem polypeptidet af interesse og det mindst ene motiv, fortrinsvis hvori spaltningsstedet er et Faktor X- eller et Glu-C-spaltningssted.
4. Fremgangsmåde ifølge krav 3, hvori trin c) efterfølges af spaltning af det cykliserede proteinholdige stof ved spaltningsstedet for at frigøre polypeptidet af interesse.
5. Fremgangsmåde ifølge krav 1, hvori det proteinholdige stof er et polypeptid af interesse, hvori en del erstattes af det mindst ene motiv, sådan at motivet er en integreret del af polypeptidet af interesse.
6. Fremgangsmåde ifølge ethvert af de foregående krav, hvori trinene a) og b) udføres i en værtscelle, der omfatter det mindst ene lantibiotiske enzym, som er i stand til at danne en thioetherbrobinding mellem X1 og X2, hvilken værtscelle er forsynet med en nukleinsyresekvens, som koder det proteinholdige forløberstof.
7. Fremgangsmåde ifølge ethvert af de foregående krav, hvori Tag omfatter sekvensen Arg-Gly-Asp.
8. Fremgangsmåde ifølge ethvert af krav 1-6, hvori Tag omfatter en streptavidin-bindingssekvens, som kan binde streptavidin med en dissocieringskonstant mindre end 10 μΜ, fortrinsvis hvori streptavidin-bindingssekvensen er valgt fra gruppen bestående af His-Pro-Gly, Flis-Pro-Lys, His-Pro-Met, His-Pro-GIn og His-Pro-Gln-Phe, fortrinsvis hvori streptavidin-bindingssekvensen er His-Pro-GIn eller His-Pro-GIn-Phe.
9. Fremgangsmåde ifølge krav 8, hvori motivet X1-Tag-X2 består af en ami-nosyresekvens valgt fra gruppen bestående af Dha- His-Pro-GIn-Phe-Cys; Dhb-His-Pro-GIn-Phe-Cys; Ser- His-Pro-GIn-Phe-Cys; Thr- His-Pro-GIn-Phe-Cys; Cys-His-Pro-GIn-Phe-Dha; Cys- His-Pro-GIn-Phe-Dhb; Cys- His-Pro-GIn-Phe-Ser; Cys-His-Pro-GIn-Phe-Thr; Dha- His-Pro-GIn-Cys; Dhb- His-Pro-GIn-Cys; Ser- His-Pro-Gln-Cys; Thr- His-Pro-GIn-Cys; Cys- His-Pro-GIn-Dha; Cys- His-Pro-GIn-Dhb; Cys- His-Pro-GIn-Ser; Cys- His-Pro-GIn-Thr; Ser- His-Pro-GIn-Phe -Lys; Thr- His-Pro-GIn-Phe-Lys; Lys- His-Pro-GIn-Phe -Ser; Lys-His-Pro-GIn-Phe-Thr; Dha- His-Pro-GIn-Phe -Lys; Dhb- His-Pro-GIn-Phe-Lys; Lys-His-Pro-GIn -Dha; Lys- His-Pro-GIn-Dhb; Ser- His-Pro-GIn -Lys; Thr- His-Pro-GIn Lys; Lys- His-Pro-GIn-Ser; Lys-His-Pro-GIn-Thr; Dha- His-Pro-GIn -Lys; Dhb-His-Pro-GIn-Lys; Lys-His-Pro-GIn-Dha; og Lys- His-Pro-GIn-Dhb.
10. Fremgangsmåde ifølge ethvert af de foregående krav, hvori trinene a) og b) udføres i en værtscelle omfattende lantioninproteiner LanB; LanC og LanT; LanM og LanT; LanB og LanC; eller LanB.
11. Proteinholdigt stof omfattende mindst en cyklisk tag-sekvens, hvori den cykliske tag-sekvens er cykliseret streptavidin-bindingssekvens, hvilken tag-sekvens er del af en thioetherforbundet ringstruktur, der i orienteringen N- til C- danner bro over en D-aminosyre og en L-aminosyre eller en L-aminosyre til en D-aminosyre.
12. Proteinholdigt stof ifølge krav 11, hvori den cykliske tag-sekvens omfatter eller består af en sekvens valgt fra gruppen bestående af His-Pro-Gly, His-Pro-Lys, His-Pro-Met, His-Pro-GIn og His-Pro-GIn-Phe.
13. Proteinholdigt stof ifølge krav 11 eller 12, omfattende et muteret lantibiotikum eller et lantibiotisk fragment omfattende en ringstruktur, og hvori ringstrukturen omfatter mindst et cyklisk streptavidin-bindingsmotiv, der indeholder en thio-etherbro, som i orienteringen N- til C- danner bro over en D-aminosyre til en L-aminosyre eller en L-aminosyre til en D-aminosyre.
14. Peptidbibliotek omfattende en flerhed af proteinholdige stoffer ifølge ethvert af krav 11-13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09163581A EP2267003A1 (en) | 2009-06-24 | 2009-06-24 | Biologically produced cyclic affinity tags |
PCT/NL2010/050389 WO2010151126A1 (en) | 2009-06-24 | 2010-06-23 | Biologically produced cyclic affinity tags |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2445926T3 true DK2445926T3 (da) | 2015-10-19 |
Family
ID=41064553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10728424.2T DK2445926T3 (da) | 2009-06-24 | 2010-06-23 | Biologisk fremstillede cykliske affinitetstags |
Country Status (10)
Country | Link |
---|---|
US (1) | US20120165230A1 (da) |
EP (2) | EP2267003A1 (da) |
JP (1) | JP5909812B2 (da) |
CN (1) | CN102803287A (da) |
AU (1) | AU2010263353B2 (da) |
CA (1) | CA2761471C (da) |
DK (1) | DK2445926T3 (da) |
ES (1) | ES2551855T3 (da) |
NZ (1) | NZ596259A (da) |
WO (1) | WO2010151126A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015175864A1 (en) * | 2014-05-15 | 2015-11-19 | Cleveland Heartlab, Inc. | Compositions and methods for purification and detection of hdl and apoa1 |
AU2018312075A1 (en) * | 2017-07-31 | 2020-02-20 | Osaka University | Highly versatile method of presenting cyclic peptide on protein structure |
CN113354718B (zh) * | 2021-06-21 | 2023-06-02 | 重庆市畜牧科学院 | 一种哌尼生素前体、表达盒及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6028168A (en) * | 1991-08-09 | 2000-02-22 | Winfried Kolbeck | Lanthionine bridged peptides |
US6841359B2 (en) | 2000-10-31 | 2005-01-11 | The General Hospital Corporation | Streptavidin-binding peptides and uses thereof |
DE50307984D1 (de) | 2002-03-01 | 2007-09-27 | Volker A Erdmann | Streptavidin-Bindungspeptid |
US6861236B2 (en) * | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
US6794181B2 (en) * | 2002-10-09 | 2004-09-21 | Immucell Corporation | Method of purifying lantibiotics |
US7785825B2 (en) * | 2004-01-12 | 2010-08-31 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics |
CN101115838B (zh) | 2004-12-07 | 2015-08-12 | 莫菲西斯公司 | 产生和分泌修饰的肽的方法 |
NZ566546A (en) * | 2005-08-12 | 2011-01-28 | Oragenics Inc | Differentially protected orthogonal lanthionine technology |
US20080032340A1 (en) | 2006-06-09 | 2008-02-07 | University Of Arizona | Peptide motifs for binding avidin or neutravidin |
WO2008130217A1 (en) | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
EP2405008A1 (en) * | 2010-07-06 | 2012-01-11 | LanthioPep B.V. | Bacterial surface display of thioether-bridge-containing peptides |
-
2009
- 2009-06-24 EP EP09163581A patent/EP2267003A1/en not_active Ceased
-
2010
- 2010-06-23 US US13/376,577 patent/US20120165230A1/en not_active Abandoned
- 2010-06-23 AU AU2010263353A patent/AU2010263353B2/en not_active Ceased
- 2010-06-23 CA CA2761471A patent/CA2761471C/en not_active Expired - Fee Related
- 2010-06-23 ES ES10728424.2T patent/ES2551855T3/es active Active
- 2010-06-23 CN CN2010800253560A patent/CN102803287A/zh active Pending
- 2010-06-23 NZ NZ596259A patent/NZ596259A/xx not_active IP Right Cessation
- 2010-06-23 DK DK10728424.2T patent/DK2445926T3/da active
- 2010-06-23 JP JP2012517429A patent/JP5909812B2/ja active Active
- 2010-06-23 WO PCT/NL2010/050389 patent/WO2010151126A1/en active Application Filing
- 2010-06-23 EP EP10728424.2A patent/EP2445926B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
CA2761471A1 (en) | 2010-12-29 |
CA2761471C (en) | 2018-06-12 |
EP2445926B1 (en) | 2015-08-12 |
EP2267003A1 (en) | 2010-12-29 |
JP5909812B2 (ja) | 2016-04-27 |
NZ596259A (en) | 2013-07-26 |
JP2012531199A (ja) | 2012-12-10 |
EP2445926A1 (en) | 2012-05-02 |
CN102803287A (zh) | 2012-11-28 |
US20120165230A1 (en) | 2012-06-28 |
AU2010263353A1 (en) | 2011-12-08 |
AU2010263353B2 (en) | 2016-05-12 |
WO2010151126A1 (en) | 2010-12-29 |
ES2551855T3 (es) | 2015-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chow et al. | Ligation technologies for the synthesis of cyclic peptides | |
RU2745572C2 (ru) | Модуляция специфичности структурированных белков | |
Agerberth et al. | Amino acid sequence of PR‐39: isolation from pig intestine of a new member of the family of proline‐arginine‐rich antibacterial peptides | |
Rowe et al. | The role of chemical synthesis in developing RiPP antibiotics | |
AU2006279749B2 (en) | Differentially protected orthogonal lanthionine technology | |
CN103080318A (zh) | 含硫醚桥的肽的细菌表面展示和筛选 | |
Kawakami et al. | Synthesis of histone proteins by CPE ligation using a recombinant peptide as the C-terminal building block | |
Levengood et al. | Investigation of the substrate specificity of lacticin 481 synthetase by using nonproteinogenic amino acids | |
Jakubke et al. | Peptides from A to Z: a concise encyclopedia | |
DK2445926T3 (da) | Biologisk fremstillede cykliske affinitetstags | |
US20030036628A1 (en) | p21 peptides | |
Abboud et al. | A straightforward methodology to overcome solubility challenges for N-terminal cysteinyl peptide segments used in native chemical ligation | |
Blanes-Mira et al. | Identification of SNARE complex modulators that inhibit exocytosis from an α-helix-constrained combinatorial library | |
Nguyen et al. | Making circles: Recent advance in chemical and enzymatic approaches in peptide macrocyclization | |
Lobo-Ruiz et al. | Synthetic approaches of naturally and rationally designed peptides and peptidomimetics | |
US7449544B2 (en) | p21 peptides | |
US9783800B2 (en) | Method for producing peptides having azole-derived skeleton | |
Banerjee et al. | The chemical synthesis of α-conotoxins and structurally modified analogs with enhanced biological stability | |
Chino et al. | Chemical synthesis of human β-defensin (hBD)-1,-2,-3 and-4: optimization of the oxidative folding reaction | |
Frost et al. | Macrocyclic Organo‐Peptide Hybrids by Intein‐Mediated Ligation: Synthesis and Applications | |
Dickman | Synthesis and Conformational Studies of the Lipid II-Binding Rings of Nisin and Mutacin I | |
Wang | Developing Functional Peptides as Synthetic Receptors, Binders of Protein and Probes for Bacteria Detection | |
Aron et al. | The diverse roles of J-proteins, the obligate Hsp70 co-chaperone | |
Zhu | Preparation of dehydropeptides and their application in the convergent synthesis of peptide conjugates | |
Chen | Ionic liquids as novel reaction media for the chemical synthesis of peptides |